While Novo is struggling to keep up with demand for its obesity drugs, U.S. rival Eli Lilly sees supply restraints easing.

Researchers found that patients with obesity had an average weight loss of 12.9% with semaglutide vs 5.6% with liraglutide ...

The European market is facing shortages of Novo Nordisk's (NYSE:NVO) injectable glucagon-like peptide-1 receptor agonist (GLP ...

Given Wegovy is a semaglutide, there is very strong evidence it can help people lose weight and maintain this weight loss. A ...

Praxis Precision Medicines Inc. (NASDAQ:PRAX) released topline results for its EMBOLD Phase 2 proof-of-concept study evaluating relutrigine in SCN2A and SCN8A developmental and epileptic ...